Candesartan-the next anti-amyloid drug?

Published in: Brain communications (2022)

This scientific commentary refers to 'Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease' by Hajjar et al. (https://doi.org/10.1093/braincomms/fcac270).

Keyphrases

blood pressure
parkinson disease
cognitive decline